Pilot study of combination chemotherapy using irinotecan plus S-1 for metastatic pancreatic cancer.

Abstract

OBJECTIVE:

The aim of this study was to evaluate the efficacy and safety of a combination regimen using irinotecan plus S-1 in patients with metastatic pancreatic cancer.

METHODS:

Based on the results of our previous phase I/II study in patients with gastric and colorectal cancer, we initiated a regimen with irinotecan at 100 mg/m(2) on days 1 and 15 and S-1 at 80 mg/m(2) starting at day 1 for 14 consecutive days, followed by a 14-day rest period. This treatment was repeated every 28 days.

RESULTS:

From November 2003 to December 2006, a total of 16 patients were enrolled. All patients presented with metastatic disease. Six patients had received prior gemcitabine. The median number of treatment cycles was 4 (range 1-16) and the response rate was 43.7% (95% confidence interval 19.5-68.1). The median time to progression was 4.9 months, and the median survival time was 11.3 months. Grade 3-4 neutropenia developed in 5 of 16 patients and grade 3 diarrhea in 1 patient.

CONCLUSIONS:

The combination of irinotecan and S-1 is feasible and promising for pancreatic cancer. Further evaluation of this combination chemotherapy is required.

• Authors: Kohei Shitara, Yoshito Komatsu, Satoshi Yuki, Masaki Munakata, Osamu Muto, Sen Shimaya, Yuh Sakata
• Journal: Oncology (Oncology) Vol. 75 Issue 1-2 Pg. 67-70 ( 2008) ISSN: 1423-0232 [Electronic] Switzerland
• PMID: 18753799 (Publication Type: Clinical Trial, Journal Article)
• Copyright: Copyright 2008 S. Karger AG, Basel.

Chemical References

• Drug Combinations
• S 1 (combination)
• Tegafur
• Oxonic Acid
• Irinotecan
• Camptothecin

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects)
• Camptothecin (administration & dosage, adverse effects, analogs & derivatives)
• Drug Combinations
• Feasibility Studies
• Female
• Humans
• Irinotecan
• Male
• Middle Aged
• Oxonic Acid (administration & dosage, adverse effects)
• Pancreatic Neoplasms (drug therapy, secondary)
• Pilot Projects
• Prospective Studies
• Tegafur (administration & dosage, adverse effects)
• Treatment Outcome